CellProtect Biotechnology develops innovative therapies for the treatment of diabetes mellitus and other chronic degenerative diseases of high epidemiological relevance and great social and economic impact. CellProtect Biotechnology also acts as a Contract Research Organization (CRO), providing support to the pharmaceutical and biotechnological industries in drug development with a wide range of in vitro and in vivo preclinical services.
